Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metazocine SCHEMBL13353229 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL21994208 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL12013732 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL1649365 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL12049577 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL29387774 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL15866689 | 0.92 | SIGMAR1 (0.85) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12267534 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12324824 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12716235 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7111 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12564597-B2 | Ibogaine analogs as therapeutics for neurological and psychiatric disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE OF NEW YORK (US) | 2026-03-03 | — | — | US | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | claimed |
| US-4882335-A | Method for treating alcohol-drinking response | ALKO LIMITED (FI) | 1989-11-21 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| US-4546103-A | Method of treating weight loss disorders | HUEBNER HANS F | 1985-10-08 | — | — | US | claimed |
| US-4464378-A | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-08-07 | — | — | US | claimed |
| US-4434168-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-02-28 | — | — | US | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4267182-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1981-05-12 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |